Based on the Madrigal Pharmaceuticals Inc stock forecast from 10 analysts, the average analyst target price for Madrigal Pharmaceuticals Inc is USD 377.14 over the next 12 months. Madrigal Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Madrigal Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Madrigal Pharmaceuticals Inc’s stock price was USD 307.78. Madrigal Pharmaceuticals Inc’s stock price has changed by -1.97% over the past week, -11.65% over the past month and +32.11% over the last year.
No recent analyst target price found for Madrigal Pharmaceuticals Inc
No recent average analyst rating found for Madrigal Pharmaceuticals Inc
Company Overview Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Read Less
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treatin...Read More
Frequently Asked Questions About Madrigal Pharmaceuticals Inc (MDGL) Stock
Based on ratings from 10 analysts Madrigal Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on MDGL's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for MDGL is USD 377.14 over the next 12 months. The maximum analyst target price is USD 427 while the minimum anlayst target price is USD 236.
Unfortunately we do not have enough data on MDGL's stock to indicate if its overvalued.
The last closing price of MDGL's stock was USD 307.78.
The most recent market capitalization for MDGL is USD 7.54B.
Based on targets from 10 analysts, the average taret price for MDGL is projected at USD 377.14 over the next 12 months.
This means that MDGL's stock price may go up by +22.54% over the next 12 months.
We can't find any ETFs which contains Madrigal Pharmaceuticals Inc's stock.
As per our most recent records Madrigal Pharmaceuticals Inc has 528 Employees.
Madrigal Pharmaceuticals Inc's registered address is Four Tower Bridge, West Conshohocken, PA, United States, 19428.
You can get more information about it from Madrigal Pharmaceuticals Inc's website at https://www.madrigalpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Madrigal Pharmaceuticals Inc (MDGL) Stock
Based on ratings from 10 analysts Madrigal Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on MDGL's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for MDGL is USD 377.14 over the next 12 months. The maximum analyst target price is USD 427 while the minimum anlayst target price is USD 236.
Unfortunately we do not have enough data on MDGL's stock to indicate if its overvalued.
The last closing price of MDGL's stock was USD 307.78.
The most recent market capitalization for MDGL is USD 7.54B.
Based on targets from 10 analysts, the average taret price for MDGL is projected at USD 377.14 over the next 12 months.
This means that MDGL's stock price may go up by +22.54% over the next 12 months.
We can't find any ETFs which contains Madrigal Pharmaceuticals Inc's stock.
As per our most recent records Madrigal Pharmaceuticals Inc has 528 Employees.
Madrigal Pharmaceuticals Inc's registered address is Four Tower Bridge, West Conshohocken, PA, United States, 19428.
You can get more information about it from Madrigal Pharmaceuticals Inc's website at https://www.madrigalpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MDGL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
